Imbalance of von Willebrand factor and its cleaving protease ADAMTS 13 during systemic inflammation superimposed on advanced cirrhosis

Liver International

Volumn 35, Issue 1, 2015, Pages 37-45

  Reuken, Philipp A ^a   Kussmann, Anna ^a,b   Kiehntopf, Michael ^a   Budde, Ulrich ^c   Stallmach, Andreas ^a   Claus, Ralf A ^a,b   Bruns, Tony ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

Author keywords

Cirrhosis; Coagulation; Haemostasis; Infections; Inflammation; Portal hypertension

Indexed keywords

FIBRIN; GLYCOPROTEIN IB; LIPOPOLYSACCHARIDE BINDING PROTEIN; RISTOCETIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; THROMBIN RECEPTOR;

ACUTE KIDNEY FAILURE; ACUTE PHASE RESPONSE; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BLOOD CLOTTING; CHILD PUGH SCORE; CLINICAL FEATURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; LEUKOCYTE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PROTEIN AGGREGATION; PROTEIN FUNCTION; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; BLOOD; COMPLICATION; METABOLISM; NONPARAMETRIC TEST; PHOTOMETRY;

ADAM PROTEINS; HUMANS; LIVER CIRRHOSIS; NEPHELOMETRY AND TURBIDIMETRY; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VON WILLEBRAND FACTOR;

EID: 84921019782     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12657     Document Type: Article

References (43)

1. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
2. Van Mourik JA, Boertjes R, Huisveld IA, et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-85.
3. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
4. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001; 130: 475-80.
5. Tsai H-M. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2003; 23: 388-96.
6. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-34.
7. Kremer Hovinga JA, Zeerleder S, Kessler P, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007; 5: 2284-90.
8. Bockmeyer CL, Claus RA, Budde U, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93: 137-40.
9. Lattuada A, Rossi E, Calzarossa C, et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88: 1029-34.
10. Reiter RA, Varadi K, Turecek PL, et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 2005; 93: 554-8.
11. Claus RA, Bockmeyer CL, Sossdorf M, et al. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure? Curr Mol Med 2010; 10: 236-48.
12. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
13. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
14. Zhou W, Inada M, Lee T-P, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85: 780-8.
15. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-4.
16. Niiya M, Uemura M, Zheng XW, et al. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost 2006; 4: 1063-70.
17. Watanabe N, Ikeda H, Kume Y, et al. Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis. Thromb Haemost 2009; 102: 389-96.
18. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
19. Takaya H, Uemura M, Fujimura Y, et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the child-turcotte-pugh score and the model for end-stage liver disease score. Hepatol Res 2012; 42: 459-72.
20. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-29.
21. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
22. Cao W, Niiya M, Zheng X, et al. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008; 6: 1233-5.
23. Bruns T, Zimmermann HW, Stallmach A. Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol 2014; 20: 2542-54.
24. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
25. Cazzaniga M, Dionigi E, Gobbo G, et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-82.
26. Cervoni J-P, Thévenot T, Weil D, et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012; 56: 1299-304.
27. Reuken PA, Kiehntopf M, Stallmach A, et al. Mid-regional pro-adrenomedullin (MR-proADM): an even better prognostic biomarker than C-reactive protein to predict short-term survival in patients with decompensated cirrhosis at risk of infection? J Hepatol 2012; 57: 1156-8.
28. Zimmermann HW, Reuken PA, Koch A, et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med 2013; 274: 86-100.
29. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37. e9.
30. Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-83.
31. Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012; 56: 1439-47.
32. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
33. Mehta R, Kellum J, Shah S, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
34. Bruns T, Peter J, Hagel S, et al. The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection. Clin Exp Immunol 2011; 164: 346-56.
35. Bockmeyer CL, Reuken PA, Simon TP, et al. ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition. Thromb Haemost 2011; 105: 145-53.
36. Maieron A, Salzl P, Peck-Radosavljevic M, et al. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014; 39: 331-8.
37. Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 193-7.
38. Sadler JE. Biomedicine. Contact-how platelets touch von Willebrand factor. Science 2002; 297: 1128-9.
39. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
40. Mehta G, Mookerjee RP, Sharma V, et al. Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol-related acute-on-chronic liver failure. Liver Int 2014; doi: 10.1111/liv.12559.
41. Mehta G, Gustot T, Mookerjee RP, et al. Inflammation and portal hypertension - the undiscovered country. J Hepatol 2014; 61: 155-63.
42. Mura VL, Reverter JC, Flores-Arroyo A, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011; 60: 1133-8.
43. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56. e5.